Holen Sie sich die Stockscreener-App
13.37
3.33%
-0.455
Schlusskurs vom Vortag:
$13.82
Offen:
$13.83
24-Stunden-Volumen:
889.64K
Relative Volume:
0.13
Marktkapitalisierung:
$2.48B
Einnahmen:
$93.95M
Nettoeinkommen (Verlust:
$-129.87M
KGV:
-14.85
EPS:
-0.9
Netto-Cashflow:
$-202.88M
1W Leistung:
-2.12%
1M Leistung:
-23.57%
6M Leistung:
+56.07%
1J Leistung:
+11.89%
1-Tages-Spanne:
$13.29
$13.91
1-Wochen-Bereich:
$13.22
$14.51
52-Wochen-Spanne:
$5.28
$21.73
Wave Life Sciences Ltd Stock (WVE) Company Profile
Firmenname
Wave Life Sciences Ltd
Sektor
Branche
Telefon
617-949-2900
Adresse
7 STRAITS VIEW, SINGAPORE
Vergleichen Sie WVE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
WVE
Wave Life Sciences Ltd
|
13.37 | 2.57B | 93.95M | -129.87M | -202.88M | -0.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.89 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.65 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.59 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.52 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-12 | Bestätigt | Wedbush | Outperform |
| 2025-12-09 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-08-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-07-28 | Eingeleitet | Oppenheimer | Outperform |
| 2025-07-16 | Eingeleitet | Citigroup | Buy |
| 2025-06-11 | Fortgesetzt | Raymond James | Outperform |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Eingeleitet | Wedbush | Outperform |
| 2025-02-25 | Eingeleitet | Jefferies | Buy |
| 2024-10-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-09-27 | Fortgesetzt | JP Morgan | Overweight |
| 2024-09-19 | Eingeleitet | B. Riley Securities | Buy |
| 2024-09-09 | Eingeleitet | JP Morgan | Overweight |
| 2024-05-15 | Eingeleitet | Wells Fargo | Overweight |
| 2023-12-19 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | Eingeleitet | Raymond James | Outperform |
| 2023-05-24 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-31 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-11-01 | Eingeleitet | Guggenheim | Buy |
| 2019-07-15 | Eingeleitet | Cowen | Market Perform |
| 2019-04-17 | Bestätigt | H.C. Wainwright | Buy |
| 2018-08-07 | Eingeleitet | Stifel | Buy |
| 2018-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-19 | Bestätigt | Mizuho | Buy |
| 2017-02-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-11-10 | Fortgesetzt | Leerink Partners | Outperform |
| 2015-12-07 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-12-07 | Eingeleitet | Jefferies | Buy |
| 2015-12-07 | Eingeleitet | Leerink Partners | Outperform |
| 2015-12-07 | Eingeleitet | Sun Trust Rbsn Humphrey | Buy |
Alle ansehen
Wave Life Sciences Ltd Aktie (WVE) Neueste Nachrichten
Volatility Watch: Can Wave Life Sciences Ltd beat the S P 500Dollar Strength & Step-by-Step Trade Execution Guides - baoquankhu1.vn
WAVE Life Sciences Ltd. $WVE Shares Sold by Emerald Advisers LLC - MarketBeat
WAVE Life Sciences Ltd. (NASDAQ:WVE) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
US Stocks Recap: Will Wave Life Sciences Ltd. outperform small cap indexes2025 AllTime Highs & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Wave Life Sciences Ltd. (WVE) Stock Analysis: Biotechnology Leader with 133.86% Potential Upside - DirectorsTalk Interviews
Should Wave’s New Obesity Data and INHBE/ALK7 Focus Require Action From Wave Life Sciences (WVE) Investors? - Yahoo Finance
A Look At Wave Life Sciences (WVE) Valuation After WVE-007 Obesity Data And Development Update - simplywall.st
First Week of March 20th Options Trading For Wave Life Sciences (WVE) - Nasdaq
How Wave Life Sciences Ltd. (WVE) Affects Rotational Strategy Timing - Stock Traders Daily
Wave Life Sciences (WVE) Deepens Obesity Bet With WVE-007 Focus – Is Its Platform Strategy Evolving? - simplywall.st
WAVE Life Sciences (NASDAQ:WVE) Shares Up 6.8%Time to Buy? - MarketBeat
Truist Financial Maintains Wave Life Sciences(WVE.US) With Buy Rating - 富途牛牛
Wave Life Sciences (WVE) Receives a Buy from Raymond James - The Globe and Mail
Bull Bear: Will Wave Life Sciences Ltd stock recover faster than peersJuly 2025 Setups & Safe Entry Trade Signal Reports - moha.gov.vn
Wave Life Sciences Ltd. (WVE) Stock Analysis: A Biotech Gem With 129% Upside Potential - DirectorsTalk Interviews
Wave Life Sciences to expand obesity drug trials in 2026 By Investing.com - Investing.com Nigeria
Wave Life Sciences to expand obesity drug trials in 2026 - Investing.com
Wave Life Sciences sets 2026 strategy, highlights obesity program - TipRanks
Wave Life Sciences Announces Plans for Phase 2a Trial of WVE-007 for Obesity and Advances RNA Editing Portfolio in 2026 - Quiver Quantitative
Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio - The Manila Times
An experimental RNA obesity treatment could allow once‑yearly dosing - Stock Titan
Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 for Obesity and Rapidly Advancing RNA Editing Portfolio - Investing News Network
WAVE Life Sciences (NASDAQ:WVE) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Wave Life Sciences stock drops 7% into JPM Healthcare Conference week — what to know next - TechStock²
Will Wave Life Sciences Ltd. stock maintain growth storyJuly 2025 Decliners & Expert Verified Movement Alerts - ulpravda.ru
Wave Life Sciences Ltd. (NASDAQ:WVE) May Have Run Too Fast Too Soon With Recent 30% Price Plummet - 富途牛牛
WAVE Life Sciences (NASDAQ:WVE) Shares Down 4.5%Here's Why - MarketBeat
Wave Life Sciences (WVE) stock slides 6% even as biotech ETFs rise — what’s driving it now - TechStock²
Wave Life Sciences (WVE) emerges as obesity treatment contender, Oppenheimer boosts price target - MSN
Wave Life Sciences upgraded at RBC following data for obesity asset WVE-007 - MSN
Is Wave Life Sciences Ltd. (1U5) stock protected from inflationEarnings Trend Report & Real-Time Market Sentiment Reports - ulpravda.ru
Aug Patterns: Will Wave Life Sciences Ltd. stock outperform tech sector in 2025CPI Data & Daily Entry Point Trade Alerts - ulpravda.ru
How Wave Life Sciences Ltd. (1U5) stock benefits from digital adoptionEarnings Summary Report & Safe Entry Momentum Stock Tips - ulpravda.ru
Quarterly Risk: Is Wave Life Sciences Ltd. stock dividend yield sustainableMarket Growth Summary & Safe Capital Allocation Plans - ulpravda.ru
What technical charts say about Wave Life Sciences Ltd. stock2025 Momentum Check & Accurate Trade Setup Notifications - ulpravda.ru
Will Wave Life Sciences Ltd. stock outperform tech sector in 2025July 2025 Trade Ideas & Step-by-Step Swing Trade Plans - ulpravda.ru
Wave Life Sciences (WVE) Valuation In Focus As Obesity Data, Equity Raise And Conference Updates Draw Attention - simplywall.st
Is Wave Life Sciences Ltd. stock attractive for income investorsPrice Channel Trading & Unlock Patterns Humans Can’t See - ulpravda.ru
Why Wave Life Sciences Ltd. stock is rated strong buyEx-Dividend Date Alerts & Use Smart Algorithms to Pick Better Stocks - ulpravda.ru
Raymond James raises WAVE Life Sciences stock price target to $26 By Investing.com - Investing.com South Africa
Raymond James raises WAVE Life Sciences stock price target to $26 - Investing.com India
Arrowhead siRNA data in obesity mark POC for adipose delivery - BioCentury
Is Wave Life Sciences’ (WVE) Obesity Bet and Extended Cash Runway Quietly Redefining Its Risk‑Reward Profile? - simplywall.st
HC Wainwright maintains a buy rating on Wave Life Sciences Ltd. (WVE) - MSN
Growth or Bubble? Decoding Wave Life Sciences’ Stock Rise - StocksToTrade
Wave Life Sciences stock gains after Arrowhead data supports INHBE mechanism - Investing.com UK
Wave Life Sciences (WVE) Sees Stock Rise Amid Positive Weight Lo - GuruFocus
Wave Life Sciences stock jumps 17% as obesity gene-silencing race heats up - TechStock²
WAVE Life Sciences (NASDAQ:WVE) Shares Gap UpWhat's Next? - MarketBeat
Wave Life Sciences (WVE) Rises Over 18% Following Market Activit - GuruFocus
Is Wave Life Sciences’ Stock a Hidden Gem? - timothysykes.com
Finanzdaten der Wave Life Sciences Ltd-Aktie (WVE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Wave Life Sciences Ltd-Aktie (WVE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Francis Chris | See Remarks |
Jan 02 '26 |
Sale |
16.03 |
9,375 |
150,260 |
25,000 |
| GSK plc | 10% Owner |
Dec 11 '25 |
Buy |
19.00 |
1,470,000 |
27,930,000 |
18,245,691 |
| Rawcliffe Adrian | Director |
Dec 08 '25 |
Option Exercise |
5.97 |
42,000 |
250,740 |
54,700 |
| Rawcliffe Adrian | Director |
Dec 08 '25 |
Sale |
15.00 |
42,000 |
630,000 |
12,700 |
| Wagner Heidi L | Director |
Dec 08 '25 |
Option Exercise |
5.97 |
14,000 |
83,580 |
51,930 |
| Wagner Heidi L | Director |
Dec 08 '25 |
Sale |
13.50 |
14,000 |
189,000 |
44,930 |
| HENRY CHRISTIAN O | Director |
Dec 08 '25 |
Option Exercise |
5.07 |
87,000 |
440,790 |
54,700 |
| HENRY CHRISTIAN O | Director |
Dec 08 '25 |
Sale |
14.65 |
93,445 |
1,369,324 |
12,700 |
| Tan Aik Na | Director |
Dec 08 '25 |
Option Exercise |
4.85 |
119,230 |
578,270 |
70,400 |
| Tan Aik Na | Director |
Dec 08 '25 |
Sale |
13.58 |
134,218 |
1,823,158 |
25,400 |
4.38%
1.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):